Cabergoline reduces the early onset of ovarian hyperstimulation syndrome: A prospective randomized study

Carlos Carizza, Vicente Abdelmassih, Soraya Abdelmassih, Pedro Ravizzini, Lister Salgueiro, Paulo Tudech Salgueiro, Lin Tao Jine, Peter Nagy, Roger Abdelmassih

Research output: Contribution to journalArticle

76 Citations (Scopus)

Abstract

Prophylactic use of cabergoline has been associated with a decrease in the severity of ovarian hyperstimulation syndrome (OHSS). A prospective randomized study was designed to evaluate the potential of cabergoline to decrease the incidence of OHSS in high-risk patients undergoing assisted reproductive technology treatment; 166 patients with oestradiol concentrations over 4000 pg/ml on the day of human chorionic gonadotrophin (HCG) administration were evaluated. They all received 20 g routine preventive intravenous human albumin on the day of oocyte retrieval. They were then randomized into two groups: group A (n = 83) received 0.5 mg oral cabergoline per day for 3 weeks beginning on the day after oocyte retrieval, and group B (n = 83) received no medication. 'Early' OHSS was defined as being when the onset of the syndrome was initiated during the first 9 days after HCG administration, and 'late' OHSS was defined as being when the onset of the syndrome was initiated from 10 days after HCG administration. In group A, no patients progressed to 'early' OHSS and nine patients (10.8%) developed 'late' OHSS; in group B, 12 patients (15.0%) progressed to 'early' OHSS and three (3.8%) to 'late' OHSS. Although the risk of 'early' OHSS decreased significantly (P < 0.001), the risk of 'late' onset OHSS did not. The two groups presented no changes in pregnancy, implantation or miscarriages rate.

Original languageEnglish
Pages (from-to)751-755
Number of pages5
JournalReproductive biomedicine online
Volume17
Issue number6
DOIs
Publication statusPublished - Dec 2008

    Fingerprint

Keywords

  • Cabergoline
  • Early
  • Late
  • OHSS
  • Onset
  • Prevention

ASJC Scopus subject areas

  • Reproductive Medicine
  • Obstetrics and Gynaecology
  • Developmental Biology

Cite this

Carizza, C., Abdelmassih, V., Abdelmassih, S., Ravizzini, P., Salgueiro, L., Salgueiro, P. T., Jine, L. T., Nagy, P., & Abdelmassih, R. (2008). Cabergoline reduces the early onset of ovarian hyperstimulation syndrome: A prospective randomized study. Reproductive biomedicine online, 17(6), 751-755. https://doi.org/10.1016/S1472-6483(10)60401-4